Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO® (CT-P41, denosumab-bmwo) ...

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion’s Remsima surpassed 1 trillion won ($699 million) in sales last year, making it the first drug developed by a ...

Celltrion's autoimmune disease treatment, Remsima, has surpassed 1.2 trillion won ($837 million) in annual sales, making it ...

South Korean stocks opened slightly higher Tuesday, despite U.S. President Donald Trump's planned imposition of tariffs on Canadian and Mexican goods. The benchmark Korea Composite Stock Price Index ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

In recent weeks, global markets have been grappling with geopolitical tensions and concerns over consumer spending, leading to fluctuations in major indices such as the S&P 500 and Dow Jones ...

Celltrion, a major Korean biopharmaceutical firm, said Tuesday its fourth quarter net profit had skyrocketed from a year ...

Korean stocks opened slightly higher Tuesday, despite U.S. President Donald Trump's planned imposition of tariffs on Canadian ...

Celltrion Inc., a major South Korean biopharmaceutical firm, said Tuesday its fourth-quarter net profit skyrocketed from a year earlier on robust sales of biosimilar medicines and the merger with its ...

In a phase 2 trial, lusvertikimab significantly improves clinical and endoscopic outcomes in patients with moderate to severe ...